How can oxidative stress contribute to alpha-synuclein pathology/toxicity? What oxidative modifications of alpha-synuclein are relevant to the PD pathogenic process?

There is evidence of oxidative damage in brains of PD patients and anti-oxidant therapies have been explored as disease-modifying therapies for PD. Alpha-synuclein aggregation - in the form of Lewy bodies - is the pathological hallmark of PD. If it a link could be determined between these two pathogenic processes, targeting this common pathway may be a viable approach for developing novel disease-modifying therapies.

6 May 2009 06:39 PM EST
Both pathological observations and genetic studies implicate alpha-synuclein as having a central role in the genesis and progression of PD. Alpha-synuclein, however, is expressed by a wide range of ... 
4 Feb 2010 12:10 PM EST
Elevated cytosolic DA levels have been shown to result in increased neurotoxicity in cellular models of PD (Mosharov et al., 2009). In a new study published in the Journal of Neuroscience Research, ...